A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis
NCT ID: NCT00568412
Last Updated: 2015-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2007-12-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
NCT01079897
Elidel-Study: Elidel in Patients With Atopic Dermatitis
NCT00180141
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
NCT05807113
LEO 29102 Cream in the Treatment of Atopic Dermatitis
NCT01037881
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
NCT07235384
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Zarzenda applied topically twice daily for three weeks
Zarzenda
Topical cream, applied twice daily for three weeks
2
Elidel 1% cream, applied topically twice daily for three weeks
Elidel
1% cream, applied topically twice daily for three weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zarzenda
Topical cream, applied twice daily for three weeks
Elidel
1% cream, applied topically twice daily for three weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* mild to moderate atopic dermatitis
* patients in whom a treatment with topical corticosteroids in not recommended or possible
* wash out periods to be observed
Exclusion Criteria
* known immunodeficiency
* known hepatic or renal insufficiency
* acute skin infections
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401920
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.